Business Context and Reporting Period
This Form 8-K, dated September 15, 2011, reports the completion of a business combination between Alkermes, Inc. and the drug technologies business ("EDT") of Elan Corporation, plc. The transaction was consummated on September 16, 2011, under the new entity Alkermes plc (formerly Antler Science Two plc). For accounting purposes, the transaction is treated as a reverse acquisition, with Alkermes, Inc. considered the accounting acquirer.
Key Financial Metrics and Capital Structure
The filing details significant capital restructuring and asset transfers rather than operational financial results for a specific period.
- Debt Financing: Alkermes entered into $450 million in term loan facilities:
- First Lien Term Loan: $310 million, six-year term, secured by a first priority lien. Initial margin is 5.25% over LIBOR or 4.25% over the base rate.
- Second Lien Term Loan: $140 million, seven-year term, secured by a second priority lien. Initial margin is 8.00% over LIBOR or 7.00% over the base rate.
- Asset Transfer: Alkermes transferred intellectual property rights related to Bydureon (exenatide for extended-release injectable suspension) to a subsidiary in exchange for a $202.1 million interest-bearing note.
- Ownership Structure: Former Alkermes shareholders own approximately 75% of the combined company. A subsidiary of Elan (the "Elan Shareholder") owns approximately 25%.
Material Changes Versus Prior Period
The filing represents a fundamental structural change rather than a period-over-period operational comparison.
- Corporate Structure: Alkermes, Inc. merged into a subsidiary of Alkermes plc, becoming a wholly-owned subsidiary. All Alkermes common stock was converted to ordinary shares of the new company.
- Accounting Acquirer: Despite the legal merger structure, Alkermes, Inc. is the accounting acquirer. Consequently, the Company's future filings will reflect Alkermes' historical financial condition and results of operations.
- Accounting Firm: PricewaterhouseCoopers LLP (PwC) was engaged as the independent registered public accounting firm for the combined company, replacing KPMG (which audited the EDT business).
Guidance, Risks, and Unusual Items
The filing does not provide forward-looking revenue guidance or management commentary on future operational performance.
- Covenants: The new term loan facilities include restrictive covenants imposing operating and financial restrictions, including leverage ratio tests that may adjust interest margins on the First Lien facility.
- Shareholder Agreement: A Shareholder's Agreement was entered into with the Elan Shareholder, governing the terms of the 25% stake held by Elan.
- Unusual Items: The transaction involves a complex reverse acquisition structure and a significant inter-company transfer of IP rights valued at $202.1 million.
Investor Verification Checklist
- Verify the specific terms of the Shareholder's Agreement with Elan regarding the 25% ownership stake and any voting rights or exit provisions.
- Review the full text of the Term Loan Facilities (Exhibits 10.1 and 10.2) to understand the specific financial covenants and default triggers.
- Confirm the pro forma financial impact of the $202.1 million IP transfer note and the $450 million debt load on future cash flow and leverage ratios.
- Examine the Proxy Statement/Prospectus (Registration No. 333-175078) for detailed historical financial data of both Alkermes and the EDT business prior to the combination.